TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: total phaco power consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reporting mental health difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: using physical or sexual violence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in diary reported stress leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of leaks during 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in minimum lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any serious adverse event attributable to vessel dilation
Endpoint domain: Adverse events/effects
Primary endpoint: muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: locoregional failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Quantity of colony-forming units (CFUs) generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive/language scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: socioemotional development scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CF-related liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of glucose metabolism disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of improved test answers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drive for thinness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-worth contingent upon others' approval
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: gap between current body figure and ideal figure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean DLQI total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient's Global Assessment of disease severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of nonfatal myocardial infarction, nonfatal stroke, or death
Endpoint domain: Mortality/survival
Primary endpoint: risk of new-onset diabetes
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intra-operative uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clear visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in number of nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in initial period of undisturbed sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Correct inhalation technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin and mucosal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in dysthymia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost savings from non-use of social assistance
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Degree of painful sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Variables of Attention (TOVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Living Skills
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: Response rate to gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal provocation test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall treatment success rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean body weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: survival advantage
Endpoint domain: Mortality/survival
Primary endpoint: blunted prolactin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: less sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: altered 'calm' and 'high' responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in size of RAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain of RAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time of RAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of RAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores of resting state and active state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of serum β‐endorphin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of serum prostaglandin E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BALF total cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CS (Cough Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ∆Ppl(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: confidence improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: resource use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: W(max) change from Test 2 to Test 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of amniocentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity for detecting trisomy 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Circulating MMP-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating MMP-9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia levels
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Depression intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial TNF‐α concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of feto-maternal transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean relative reduction in maximal fractional area (MFA) of color pixels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence of atopic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion of Assess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Assist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Arrange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: investigator-assessed responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Apparent Density (BMAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with inadequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in patient cost for tests ordered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in specific individual tests ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No increase in adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of VTE
Endpoint domain: Mortality/survival
Primary endpoint: Difference in reaction time greater than 1 minute
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bacteroidetes:Firmicutes ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pain face classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentrations of aliskiren
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma aliskiren concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of neural defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: markedly effective and curative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: v-CAL gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: h-CAL gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth (weight, length, head circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2'FL uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recurrence rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conduct problem improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum knee abduction angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximum hip adduction angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximum ankle eversion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RV ejection fraction (RVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV stroke work index (RVSWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive impairment in at least one domain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Toxic adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: BUN level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of fluid administered during the first 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total glyburide oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glyburide free fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LT4 doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visibility score in the proximal part of the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction score of the endoscopist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative predictive value of NBI endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carriage rates of PCV7 vaccine types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of penicillin non-susceptible S. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: impact of swallowing training on nutritional condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: impact of swallowing training on pulmonary condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decrease in hospital and home care costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of edentulousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of remaining sound teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of decayed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative spirometric values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic quality of images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delaying DWI and other dangerous traffic violations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-last) of cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse haemodynamic effects
Endpoint domain: Adverse events/effects
Primary endpoint: decline in thyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Microleakage of composite resin restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Repeat mammogram utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: nighttime percent sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: observed agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Future temporal focus
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proactive coping
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: FMEP amplitude ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative FN function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate relief of IBS-D symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in abdominal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on NPI-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on CSDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jumping distance for SLJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jumping height for CMJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertical ground reaction force in CMJ and DJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in HS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in LLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mean symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in SHBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in free testosterone index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Control of edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year disease free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: DTCH response to autologous tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Client satisfaction with mental health services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for direct laryngoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 5-year Kaplan-Meier survival probabilities
Endpoint domain: Mortality/survival
Primary endpoint: 5-year Kaplan-Meier success rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of FFRW sensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of symptoms associated with BPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Non-fatal reinfarction
Endpoint domain: Mortality/survival
Primary endpoint: Medial cuff failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incomplete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improvement of the index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of proinflammatory cytokines (TNF-α and IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma levels of interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total plasma proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3 and C4 proteins of the complement system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: best corrected postoperative visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immunologic graft reactions
Endpoint domain: Adverse events/effects
Primary endpoint: suture loosening
Endpoint domain: Adverse events/effects
Primary endpoint: Morning PEF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Afternoon PEF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diurnal variation in PEF decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ISTH major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: motor learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pulmonary incompetence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV outflow tract gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: long-term psychosocial outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motor functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning